Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.

Clin Diabetes Endocrinol · 2018 · PMC5941332 · PMID 29760945

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A highly significant weight loss of greater than 15% from baseline was seen in 6.7% patients in the liraglutide arm, but not in the dulaglutide arm [Fig. 1 ].

also in 132,142 other papers

did not reach statistical significanceno p-value reported

But this did not reach statistical significance probably due to the small number of patients.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.